Moberg Pharma replaces CRO in Phase 3 studies for MOB-015
STOCKHOLM, November 20th, 2017, Moberg Pharma AB (OMX: MOB) is replacing the CRO with primary responsibility for the two ongoing Phase 3 studies for MOB-015. This is a key step in the extensive action program now underway to finalize patient recruitment, with the goal of delivering strong topline results in 2019 without further external financing. The actions fall within the updated timeline presented on November 8, 2017, which allows for handoff to a new CRO.Two parallel Phase 3 studies for MOB-015 have been underway in the EU and North America for the last year. The CRO (contract research